Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Pancreatic Neoplasms 35Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 15Lung Neoplasms 13Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Neoplasms 10Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Head and Neck Neoplasms 4Carcinoma, Pancreatic Ductal 4Stomach Neoplasms 3Neoplasms by Site 3Gastrointestinal Neoplasms 3Carcinoma 3Adenocarcinoma 3Vaccinia 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thymoma 1

Interventions

Paclitaxel 24Bevacizumab 21Carboplatin 20liposomal doxorubicin 15Specimen Handling 14olaparib 13Magnetic Resonance Spectroscopy 13Gemcitabine 10Topotecan 9pembrolizumab 8Biopsy 8Taxes 7Immunoglobulin G 6Disulfides 6niraparib 5Doxorubicin 5mirvetuximab soravtansine 4cediranib 4oregovomab 3Nivolumab 3Drug Therapy 3Docetaxel 3Cyclophosphamide 3Cisplatin 3sarilumab 2rucaparib 2cemiplimab 2berzosertib 2adavosertib 2Saline Solution 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × 130-nm albumin-bound paclitaxel × 90 days × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡